Royalty Pharma (RPRX) CFO gets 26,626-share equity performance award

Rhea-AI Filing Summary

Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported an indirect equity award of Class A Ordinary Shares. On February 11, 2026, an affiliated entity, TPC RP EPA1 LLC, acquired 26,626 Class A shares at $0 per share in an exempt transaction under Rule 16b-3 tied to the settlement of equity performance awards. Following this grant, TPC RP EPA1 LLC holds 49,511 Class A shares indirectly for Coyne. The filing also notes additional indirect holdings through related LLCs and retirement accounts, plus partnership and Class E Ordinary Share interests exchangeable into 6,448,180 and 1,807,277 Class A shares, respectively, with the Class E interests subject to vesting conditions.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Coyne Terrance P.

Role EVP & CFO

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	26,626	$0.00	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 49,511 shares (Indirect, TPC RP EPA1 LLC); Class A Ordinary Shares — 1,500 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/13/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	02/11/2026		A		26,626(1)	A	$0	49,511	I	TPC RP EPA1 LLC
Class A Ordinary Shares								164,580	I	By TPC RP 2021, LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,807,277 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Royalty Pharma (RPRX) report for its CFO?

Royalty Pharma’s CFO reported an indirect equity award. An affiliated entity, TPC RP EPA1 LLC, acquired 26,626 Class A Ordinary Shares at $0 per share as an exempt Rule 16b-3 grant tied to settling equity performance awards.

How many Royalty Pharma (RPRX) shares does TPC RP EPA1 LLC hold after the award?

TPC RP EPA1 LLC now holds 49,511 Class A shares. This reflects the 26,626-share equity performance award settlement on February 11, 2026, increasing the indirect holdings reported for EVP & CFO Terrance P. Coyne.

Was the Royalty Pharma (RPRX) CFO’s share acquisition an open-market purchase?

No, the shares were not bought on the open market. The 26,626 Class A Ordinary Shares were acquired at $0 per share as an exempt Rule 16b-3 transaction in connection with settling equity performance awards, rather than a cash purchase.

What additional exchangeable interests related to Royalty Pharma (RPRX) does the CFO report?

The filing discloses large exchangeable interests. Coyne and related family vehicles hold RPI US Partners 2019, LP interests exchangeable into 6,448,180 Class A shares and Royalty Pharma Holdings Ltd Class E shares exchangeable into 1,807,277 Class A shares, subject to vesting.

How are the Royalty Pharma (RPRX) CFO’s holdings structured across entities?

Holdings are spread across several vehicles. Indirect Class A holdings are reported through TPC RP EPA1 LLC, TPC RP 2021, LLC, the spouse’s IRA, the reporting person’s IRA, and the spouse’s account, in addition to the large exchangeable partnership and Class E share interests.

What regulatory rule applies to the Royalty Pharma (RPRX) CFO’s equity award?

The acquisition is described as exempt under Rule 16b-3. The 26,626 Class A Ordinary Shares were granted in connection with the settlement of equity performance awards, qualifying as an exempt insider acquisition for reporting purposes.